MiroBio is founded by leading immunologists at the University of Oxford who have spent over 15 years focussed on understanding the mechanisms which underlie T-cell signalling. The technology is based on an IP portfolio of novel antibodies with the ability to activate inhibitory co-receptors on the surface of immune cells, with a deep mechanistic understanding, MiroBio is able to optimise these antibodies to create immune-modulatory therapies which have shown remarkable efficacy in preclinical models of disease. MiroBio is now building out the team and the platform looking for strong antibody-development expertise to take the lead compounds to clinical proof-of-concept. MiroBio is a spin-out from the Oxford with an investment of £27M ($34M) from Samsara Biocapital, Oxford Sciences Innovations, Advent Life Sciences and SR One. The company is based in Oxford, retaining close links to the world-class immunology expertise and clinical trial experience within the University.